97 results on '"Jordan, Emmet"'
Search Results
52. YES1amplification: a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics
53. Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
54. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype
55. Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy
56. Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
57. DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma
58. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
59. A prospective analysis of germline alterations (GA) in biliary tract cancer (BTC).
60. Brain metastases (BM) in pancreatic ductal adenocarcinoma (PDAC): Clinical and molecular characteristics.
61. YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing.
62. Prospective assessment for pathogenic germline alterations (PGA) in pancreas cancer (PAC).
63. Treatment and outcomes of small cell neuroendocrine carcinoma of the cervix (SCCC).
64. MP98-04 DEFECTIVE ERCC2 CONFERS INCREASED CISPLATIN AND IONIZING RADIATION SENSITIVITY IN BLADDER CANCER CELLS
65. MP48-17 PHENOTYPIC-GENOTYPIC CORRELATION OF TP53 AND RB1 IN UROTHELIAL CARCINOMA
66. Effect of defective ERCC2 on cisplatin and ionizing radiation (IR) sensitivity in bladder cancer cells.
67. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition
68. Obesity and cardiovascular risk in an oncology day ward population.
69. Systemic therapy for biliary cancers
70. Comprehensive molecular profiling and analysis of mutual exclusivity of genetic aberrations (MEGA) of intra- and extrahepatic cholangiocarcinomas (IHC and EHC) evaluation of prognostic features and potential targets for intervention.
71. Association of outcomes and co-occuring genomic alterations in patients with KRAS-mutant non-small cell lung cancer.
72. Next generation sequencing (NGS) in lung adenocarcinoma (LA) as a guide to treatment selection.
73. Concurrent genetic alterations identified by next-generation sequencing in pre-treatment, metastatic EGFR-mutant lung cancers.
74. Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.
75. Identifying HER2 mutation, amplification, and HER2 protein overexpression as therapeutic targets in lung cancers.
76. Genomic profiling of pancreas ductal adenocarcinoma (PDA), actionability, and correlation with clinical phenotype.
77. MP88-13 MUTATIONAL LANDSCAPE OF PRIMARY BLADDER AND URACHAL ADENOCARCINOMA
78. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer
79. Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.
80. Assessment of genomic alterations in adenosquamous carcinoma of the pancreas (ASCOP).
81. YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.
82. Association of somatic mutations in DNA damage repair (DDR) genes with efficacy of platinum-based chemotherapy in advanced urothelial carcinoma.
83. Split-dose cisplatin as an alternative to every-3-week dosing when using cisplatin/gemcitabine to treat advanced urothelial cancer.
84. Clinical and Molecular Analysis of Adenosquamous Carcinoma of the Pancreas.
85. Use of cold cap in cancer patients: A single institution experience.
86. Inappropriate prescribing in older patients with cancer.
87. Uptake of adjuvant chemotherapy (AC) for colon cancer in older and younger patients (pts) in the Irish population.
88. Colorectal carcinoma (CRC) management approach in octogenarians and over a single institute experience.
89. Vemurafenibfor the treatment of melanoma
90. Positron emission tomography/computed tomography (PET/CT) as a biomarker of pathologic response to neoadjuvant chemotherapy in breast carcinoma.
91. Breast cancer in Irish families with Lynch syndrome.
92. Social supports in patients with cancer attending an Irish cancer center: a cross-sectional study.
93. miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review.
94. AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling.
95. Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.
96. The role of novel biologics in biliary cancers.
97. Vemurafenib for the treatment of melanoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.